<?xml version="1.0" encoding="UTF-8"?>
<p>Interestingly, in ARDS animal models, 
 <italic>ACE2</italic> knockdown mice experience more severe symptoms [
 <xref rid="B58-ijms-21-03474" ref-type="bibr">58</xref>]. 
 <italic>ACE2</italic> gene deletion causes progressive cardiac fibrosis [
 <xref rid="B63-ijms-21-03474" ref-type="bibr">63</xref>], whereas 
 <italic>ACE2</italic> deficient mice result in renal injury and glomerulosclerosis [
 <xref rid="B64-ijms-21-03474" ref-type="bibr">64</xref>,
 <xref rid="B65-ijms-21-03474" ref-type="bibr">65</xref>]. These alterations are reversed or ameliorated by treatment with ACE-inhibitors or Ang-receptors blocker (ARBs) [
 <xref rid="B37-ijms-21-03474" ref-type="bibr">37</xref>,
 <xref rid="B63-ijms-21-03474" ref-type="bibr">63</xref>,
 <xref rid="B66-ijms-21-03474" ref-type="bibr">66</xref>,
 <xref rid="B67-ijms-21-03474" ref-type="bibr">67</xref>], whether or not they are combined with infusion of a soluble form of recombinant human ACE2 (rhACE2) [
 <xref rid="B68-ijms-21-03474" ref-type="bibr">68</xref>,
 <xref rid="B69-ijms-21-03474" ref-type="bibr">69</xref>,
 <xref rid="B70-ijms-21-03474" ref-type="bibr">70</xref>]. Intuitively, this strategy could also be a possible treatment for COVID-19 patients with a double effect: excessive soluble rhACE2 could competitively bind and neutralize the SARS-CoV-2 virus, and rescue the cellular ACE2 activity counteracting unescapably unrestrained ACE1 activity to contrast lung injury. In summary, the ACE1/ACE2 balance is crucial in contrasting organ dysfunction, so a direct or indirect increase in ACE2 expression together with a modulation of ACE1 activity may be helpful to avoid pulmonary disease progression (
 <xref ref-type="fig" rid="ijms-21-03474-f002">Figure 2</xref>) [
 <xref rid="B37-ijms-21-03474" ref-type="bibr">37</xref>,
 <xref rid="B58-ijms-21-03474" ref-type="bibr">58</xref>,
 <xref rid="B71-ijms-21-03474" ref-type="bibr">71</xref>,
 <xref rid="B72-ijms-21-03474" ref-type="bibr">72</xref>,
 <xref rid="B73-ijms-21-03474" ref-type="bibr">73</xref>,
 <xref rid="B74-ijms-21-03474" ref-type="bibr">74</xref>]. Accordingly, several international societies recommend not to stop treatments with RAS pathway antagonists in cardiovascular disease patients [
 <xref rid="B40-ijms-21-03474" ref-type="bibr">40</xref>], and a recent editorial comments on several publications discussing the positive effects of RAS inhibitors during COVID-19 [
 <xref rid="B75-ijms-21-03474" ref-type="bibr">75</xref>].
</p>
